Literature DB >> 32509816

Retrospective analysis of 45 cases of localized retroperitoneal Castleman disease from a single center.

Jian-Qiang Tang1, He-Kai Chen1, Xin Wang1, Ming-Yue Wang2, Yan Xiong3, He Wang4, Yin-Mo Yang1.   

Abstract

BACKGROUND: Castleman disease (CD) is a rare lymphoproliferative disease characterized by high heterogeneity in clinical manifestation and prognosis. This study aimed to summarize clinical features of localized retroperitoneal CD and our experiences to improve the diagnosis and treatment of this disease.
METHODS: Clinical data of 45 patients with localized retroperitoneal CD were retrospectively analyzed. The differences in clinical features between groups with and without paraneoplastic pemphigus (PNP) were compared. Survival was analyzed between groups depending on whether complicating with PNP, bronchiolitis obliterans (BO), gender, age and uni-centric CD (UCD)/multi-centric CD (MCD), respectively.
RESULTS: Significant differences were observed between patient groups in the prevalence of retroperitoneal CD with PNP complicated with BO (P=0.010), the constituent ratios of initial symptoms (P<0.001) and the duration from appearance of the initial symptoms to being diagnosed (P=0.009). Among 45 cases, 43 tumors had clear margins and intact envelops and were completely resected, 40 patients were cured or significantly relieved, 3 patients were not significantly relieved, 2 patients received palliative surgical therapy and eventually relapsed and died after surgery. There were significant differences in the survival rate between groups depending on complication with BO, gender and age (≤40 and >40 years) (all P<0.05).
CONCLUSIONS: Prompt and complete removal of the retroperitoneal CD tumor is critical to the management of this disease, as palliative resection tends to cause relapse and lead to a poor prognosis. Retroperitoneal CD patients with PNP may develop complications from BO leading to death. Complication with PNP, complication with BO, male gender and age ≥40 years were identified as prognostic risk factors for patients with localized retroperitoneal CD. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Giant lymph node hyperplasia; paraneoplastic pemphigus (PNP); retroperitoneal; surgical resection

Year:  2020        PMID: 32509816      PMCID: PMC7262626          DOI: 10.21037/hbsn.2019.05.05

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  21 in total

1.  Localized mediastinal lymphnode hyperplasia resembling thymoma.

Authors:  B CASTLEMAN; L IVERSON; V P MENENDEZ
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

2.  Classic case of unicentric mixed-type Castleman's disease.

Authors:  Ravi Nagubandi; Yanhua Wang; Janice P Dutcher; Prakashchandra M Rao
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  Surgical Management of Unicentric Castleman's Disease in the Abdomen.

Authors:  Min-Sang Kim; Jae-Kyun Ju; Young Kim
Journal:  Ann Coloproctol       Date:  2014-04-25

4.  Case 172: Retroperitoneal Castleman disease (hyaline vascular type).

Authors:  Patricia Sims Poole; Eric Y Chang; Cynthia S Santillan
Journal:  Radiology       Date:  2011-08       Impact factor: 11.105

5.  Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia.

Authors:  G J Anhalt; S C Kim; J R Stanley; N J Korman; D A Jabs; M Kory; H Izumi; H Ratrie; D Mutasim; L Ariss-Abdo
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

6.  Renal involvement in a large cohort of Chinese patients with Castleman disease.

Authors:  Damin Xu; Jicheng Lv; Yujun Dong; Suxia Wang; Tao Su; Fude Zhou; Wanzhong Zou; Minghui Zhao; Hong Zhang
Journal:  Nephrol Dial Transplant       Date:  2011-05-19       Impact factor: 5.992

Review 7.  Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China.

Authors:  Jing Wang; Xuejun Zhu; Ruoyu Li; Ping Tu; Rengui Wang; Lanbo Zhang; Ting Li; Xixue Chen; Aiping Wang; Shuxia Yang; Yan Wu; Haizhen Yang; Suzhen Ji
Journal:  Arch Dermatol       Date:  2005-10

8.  Retroperitoneal Castleman disease on 99mTc DTPA renal scintigraphy.

Authors:  Le Song; Qian Yao; Xin Huang; Yanyan Zhang
Journal:  Clin Nucl Med       Date:  2012-10       Impact factor: 7.794

9.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

10.  Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital.

Authors:  Jin Mei Luo; Shan Li; Hui Huang; Jian Cao; Kai Xu; Ya Lan Bi; Rui E Feng; Cheng Huang; Ying Zhi Qin; Zuo Jun Xu; Yi Xiao
Journal:  BMC Pulm Med       Date:  2015-04-09       Impact factor: 3.317

View more
  1 in total

1.  Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.

Authors:  Dijiao Tang; Yuetong Guo; Yi Tang; Hongxu Wang
Journal:  Ther Clin Risk Manag       Date:  2022-04-26       Impact factor: 2.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.